Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...

Pfizer’s respiratory syncytial virus (RSV) vaccine has been approved by the European Commission (EC) to prevent ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

Australian medicines regulator, the Therapeutic Goods Administration (TGA), has granted approval for mRESVIA (mRNA-1345), an ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), ...

Moderna (MRNA) announced that the Australian Therapeutic Goods Administration has granted approval for mRESVIA, an mRNA respiratory syncytial ...

Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...

The pipeline features several drugs, which are being investigated across different phases of development; 60% of the drug ...

Researchers at the University of Cologne have found that mRNA-based COVID-19 vaccines have a lasting impact on the innate ...

AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published its 2024 Annual Results announcement on March 30, ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...